Gubra
Morten Lundh has extensive experience in drug discovery and biomedical research, holding leadership positions such as Director of Drug Discovery Innovation at Gubra from June 2020 to November 2022, where Morten led a team focusing on innovation initiatives in drug discovery. Prior to that, Morten served as a Project Leader at Gubra, overseeing drug discovery projects and collaborations with pharmaceutical companies. Morten also held academic roles, including Assistant Professor at the Faculty of Health and Medical Sciences, UCPH, investigating insulin signaling mechanisms, and Postdoctoral Fellow at The Novo Nordisk Foundation Center for Basic Metabolic Research, conducting similar research. Morten's academic journey began with a PhD at the University of Copenhagen, concentrating on the role of Histone Deacetylases in pancreatic beta-cell death, building a strong foundation in molecular biomedicine with a Master’s degree from the University of Copenhagen and further study at The Australian National University.
This person is not in any teams
This person is not in any offices
Gubra
Founded in 2008, we are a biotech company with two primary areas of business: Preclinical contract research organization (CRO) services and proprietary early target and drug discovery programs. Our focus is the metabolic space (e.g. obesity, diabetes, NASH and gastrointestinal diseases), where we specialize in peptide chemistry, in vivo pharmacology, ex vivo assays, molecular pharmacology, histology, imaging, stereology, NGS (next generation sequencing) and bioinformatics. Gubra is an abbreviation for GUt and BRAin, the original key focus areas of our research and expertise. We work with some of the most interesting and loyal partners and customers from across the world in the pharmaceutical and biotech industry as well as academia. Through a constant focus on high quality, scientific excellence, speed and solid teamwork, we have established ourselves as a highly professional and competent partner in the market.